Study of a new drug combo for advanced HER2-positive colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer that has spread to other parts of the body or cannot be removed with surgery.
- Your cancer must test positive for HER2 (a protein on cancer cells) based on a tumor sample.
- You must not have received any previous treatment for advanced or metastatic colorectal cancer.
- You need to be in generally good health, able to take care of yourself (ECOG score 0-2), and have adequate organ function.
- You must have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan and cetuximab, for people with colorectal cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
This trial tests a new drug combination for people with advanced colorectal cancer that has a specific protein called HER2. The treatment includes a targeted drug (trastuzumab rezetecan) plus chemotherapy and another targeted drug (bevacizumab) to see if it can shrink tumors and help patients live longer.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.